Methods of treating prostate intraepithelial neoplasia with using herbal compositions

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely oncology and can be used for treating prostate intraepithelial neoplasia. The methods according to the invention involve introduction of a composition containing therapeutically effective amounts of supercritical extracts of rosemary, turmeric, origanum and ginger; and therapeutically effective amounts of water-alcohol extracts of holy basil, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, Coptis chinensis and barberry.

EFFECT: invention allows inhibiting growth of intraepithelial neoplasia cells due to antineoplastic activity of herbal extracts of the composition, inhibition of cyclooxygenase 2 and induction of apoptosis.

43 cl, 1 tbl, 2 ex

 

The level of technology

1. The technical field to which the invention relates.

The present invention relates to new methods of treatment of intraepithelial neoplasia of the prostate, including the introduction of compositions containing therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred (Ocimum sanctum), ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

2. The level of technology

Intraepithelial neoplasia of the prostate. Each year, prostate cancer is diagnosed in approximately 200000 American men, millions of undiagnosed cancer develops or hidden in microscopic form. About 80% of men over age 80 have microscopic prostate cancer, and the frequency of its detection at necropsy, approximately equal in men around the world despite significant differences in clinical diagnostics.

Intraepithelial neoplasia of the prostate ("PIN") refers to potentially precancerous total sequence of cell proliferati pavements of large and small prostatic ducts and acini. Intraepithelial neoplasia of the prostate gland is what I commonly accepted term, although to describe this state also used terms such as dysplasia, malignant transformation and intraductal carcinoma. PIN is characterized by cellular proliferation in existing ducts and acini with cytological changes similar to cancer, including enlargement of nuclei and nucleoli.

Physiological form PIN includes a comb, micropapillary, lattice and flat. Comb shape is the most common and represented 97% of all PIN. Most of the histological samples contain multiple forms, and prognostic differences between individual forms PIN no. PIN spread in prostatic ducts in 3 forms, similar to prostate cancer. The first form of the neoplastic cells replace the normal secretory epithelium of the lumen of the duct, but not affect the basal layer and the basement membrane. Under light microscopy foci PIN can be indistinguishable from the distribution of cancer in the duct. The second form is characterized by direct invasion through the wall of the duct or acinus with the destruction of the basal layer cells. When the third form of neoplastic cells penetrate between the layers of basal cells, which are sometimes described as leaf distribution.

Intraepithelial the neoplasia of the prostate in this is blasti usually considered as probable preinvasive stage adenocarcinoma of the prostate. The PIN has a high predictive value as a marker of adenocarcinoma, and its detection requires a re-biopsy for detection of concomitant or subsequent invasive carcinoma. Many studies have shown that most patients with PIN eventually develop cancer. Some studies have shown that between half and two thirds of patients diagnosed with PIN get cancer within 2-3 years. Thus, there is great need for effective treatment of the PIN in order to reduce or prevent the development of prostate cancer.

The frequency and severity of the PIN increases with patient age. PIN associated with progressive abnormalities phenotype and genotype, which are more similar to cancer than normal prostatic epithelium, showing a decrease of cell differentiation in the process of staged development of prostatic carcinogenesis. The only accepted way to identify PIN is biopsy; PIN slightly increases in the concentration of serum PSA or its derivatives and weakly identified with modern visualization techniques. There are no accepted pharmaceutical or practical surgical treatment standards PIN. Some studies suggest that antiandrogenov therapy reduces the incidence and severity PIN at some the x patients being thus one of the possible ways of chemoprophylaxis. However antiandrogenov therapy has some side effects, which will be discussed in detail below, making it sub-optimal treatment for many men.

PIN is the most significant risk factor for prostate cancer in the study of samples obtained by needle biopsy. Her role as pre-invasive stage of cancer was confirmed in two independent models in mice (see Alsikafi, et al., High-grade Prostatic Intraepithelial Neoplasia with Adjacent Atypia Is Associeted with a Higher Incidence of Cancer on Subsequent Needle Biopsy than High-grade Prostatic Intraepithelial Neoplasia Alone, Urology, 57(2):296-300 (2001); and Amin, et al., Putative Precursor Lesions of Prostatic Adenocarcinoma: Fact or Fiction? Mod. Pathol., 6(4):476-83 (1993)).

PIN combined with cancer in more than 85% of cases, but leaves intact or fragmented basal cell layer in contrast to the cancer that destroys the basal cell layer. The clinical significance of the detection PIN is based on its strong link with adenocarcinoma of the prostate, and the detection PIN in biopsies of the prostate gland requires further examination for the detection associated cancers. By itself, the PIN does not have significant effect on the concentration of serum prostate-specific antigen ("PSA"), and PSA levels do not correlate with the PIN. If all procedures are unsuccessful globarena associated cancer and in the absence of a treatment for PIN, shows careful observation of the patient with repeated surveys. Currently, in clinical practice the patient calls for repeat biopsies offer at intervals of from three to six months for two years and then at intervals of twelve months for life. Biopsies are expensive for the patient and unpleasant at the same time, and thus, there is a clear need for a method of treatment of a PIN.

Despite the absence of conventional pharmaceutical or surgical standards of practice for treatment of a PIN in the extent to which they are applied, treatment PIN includes antiandrogenov therapy and radiation therapy. Antiandrogenov therapy has some potential complications, including problems with sexual function, osteoporosis, and reduced muscle mass. Radiation therapy has possible complications, including loss of appetite, weakness, skin reactions such as redness and irritation, a burning sensation in the rectum or damage, diarrhea, cystitis and hematuria. Thus, there remains a need for alternative ways of treating prostate cancer and improved treatment of intraepithelial neoplasia of the prostate gland.

Cyclo-oxygenase inhibitors. The cyclooxygenase is an enzyme - protein complex is with different types of biochemical actions. There are at least three primary isoenzyme COX, COX-1, COX-2 and COX-3. COX-1 is a constitutive enzyme that is constantly produced with a moderate constant level. It plays an important role, for example, when the protection in the gastrointestinal tract kidney function and aggregation of blood platelets. The products of COX-2 is not constant; it varies depending on signals from various biological catalysts.

For example, in the case of inflammation and pain of arthritis COX-2 is responsible for tissue damage by oxidation of arachidonic acid, with the receipt of prostaglandins, which in turn produce inflammation. COX-3 was identified relatively recently (Chandrasekharan et al. PNAS U.S.A., 99 (21): 13926-31 (2002)). People mRNA COX-3 is expressed most abundantly in the brain and cardiac tissues. The activity of COX-3 is selectively inhibited by analgesics/antipyretics. It was assumed that the inhibition of COX-3 may represent a mechanism by which these medicines reduce pain and possibly fever.

Prostaglandins play a major role in the process of inflammation, and inhibition of production of prostaglandins, especially the production of PGG2, PGH2 and PGE2 is the purpose of this study anti-inflammatory drugs. However, conventional non-steroidal anti-inflammatory drugs ("NSAID"), which assets the us in terms induced by prostaglandins pain and swelling, associated with inflammation, is also active in influencing regulated by prostaglandins processes not associated with inflammation.

It was found that NSAIDs prevent the production of prostaglandins by inhibition of enzymes of human rights in the way arachidonic acid/prostaglandin, enzyme induction of cyclooxygenase. Traditional non-steroidal anti-inflammatory drugs, such as aspirin, act by inhibiting COX-1 and COX-2. Thus, nonspecific NSAID can have a damaging effect on the gastro-intestinal tract, kidneys, and liver; the blocking of COX-1 can make the lining of the stomach more vulnerable, and decreased production of thromboxane thins the blood, which leads to greater likelihood of gastrointestinal bleeding and can cause inadequate regulation of cellular immune function and the secretion of various cytokines.

The use of high doses of the most common NSAID can produce severe side effects, including life-threatening ulcers that limit their therapeutic potential.

COX-2 is associated with inflammation and provides a viable target of inhibition which more effectively reduces inflammation and produces less intense side effects. Thus, the researchers had the motivation for the development of selective behaviour is marketed COX-2 inhibitors to reduce inflammation and relieve the pain without damage to the gastrointestinal tract, caused by inhibition of COX-1. In addition, modern scientific understanding in this field indicates that the inhibition of COX-2 may serve an important function to prevent the normal growth of cells in the intestine, pancreas, breast tissue, and other organ systems.

Some compounds that selectively inhibit cyclooxygenase-2, is described in U.S. patent№5380738, 5344991, 5383790, 5434178, 5474995, 5510368 and the documents WO 96/06840, WO 96/03388, WO 96/03387, WO 96/25405, WO 95/15316, WO 94/15932, WO 94/27980, WO 95/00501, WO 94/13635, WO 94/20480 and WO 94/26731.

Such medicines as valdecoxib, celecoxib and rofecoksib, as it is assumed that selectively inhibit COX-2 with minimal effect on COX-1. However, despite the emphasis on the inhibition of COX-2 even these medicines, as it turns out, have serious long-term side effects such as the destruction of the digestive protective mucus and prevent normal healing processes. Thus, there is a continuing need for more specific and nonspecific inhibitors SOH-2, which avoids the side effects associated with inhibition of MOR-1.

Natural inhibitors SOH-2. Some herbs, has been found to inhibit the enzyme SOH-2. For example, Holy Basil, has been found to possess significant anti-inflammatory properties which can block ziklooksigenazny and lipoxygenase metabolic pathways of arachidonate. Ursolic acid and oleanolic acid, two of the detected phytonutrient Basilica of the sacred, as it was found to have significant activity against inhibition of MOR-2.

Similarly shogaol and gingerol, pungent components of ginger was found to inhibit cyclooxygenase.

Eugenol, the other active component of some medicinal herbs, as well as discovered, is an inhibitor of 5-lipoxygenase and has powerful anti-inflammatory and/or anti-rheumatic properties.

Scutellaria baicalensis is also how it was discovered, inhibits the enzyme SOH-2. According to the database USDA green tea contains six components that have inhibitory activity against cyclooxygenase. According to the database Napralert green tea contains fifty-one component having anti-inflammatory activity. The polyphenols in green tea, has been found to cause significant reduction in MOR-2. (+)-Catechin derived flavan-3-ol, also present in green tea, as reported, is also an inhibitor of COX-1 and COX-2. In addition, salicylic acid, another component of green tea, as well as discovered, is a COX-2 inhibitor.

Berberine, found in barberry and coptica Chinese, as well as discovered that inhibits COX-2 without inhibiting the activity of COX-1.

In U.S. patent No. 6387416 applicants who spisivaut compositions according to the invention and their use to reduce inflammation. The contents of U.S. patent No. 6387416 fully included here as a reference.

Suddenly, as further discussed below, it was determined that the composition of the invention can also be used for the treatment of intraepithelial neoplasia of the prostate gland.

Treatment of intraepithelial neoplasia of the prostate. The inventors have found that COX-2 inhibitors can be used to treat some forms of cancer. The inventors have also found that COX-2 inhibitors can be used for the treatment of intraepithelial neoplasia of the prostate. Only a very small number of patents concerning the use of selective COX-2 inhibitors for cancer treatment, and none devoted to the use of specific or non-specific COX-2 inhibitors for the treatment of intraepithelial neoplasia of the prostate. List of patents related to PIN and related non-invasive diagnostic and treatment methods using compounds that are not COX-2 inhibitors, represented by the following U.S. patents.

U.S. patent No. 5935860 issued Patierno, et al., reveals a non-surgical method for detection of intraepithelial neoplasia of the prostate based on the expression of protein uteroglobin as molecular marker PIN.

U.S. patents№№6265448, 6410043, 6413533, 6413534, 6413535 and 6632447, lent out is Steiner, et al., revealing the ways chemoprophylaxis of neoplasms of the prostate gland introduction to the subject an effective dose of the proposed specific chemoprophylactic agents to prevent relapse of prostate cancer, suppress or slow, benign prostatic hyperplasia, abnormally high level of circulating prostate-specific antigen (PSA).

U.S. patent No. 6477426 issued Fenn, et al., revealing the system solution and violations of cancerous and precancerous conditions in the prostate, as well as benign and previous injuries, including PIN, by irradiating the tissue of the prostate coherent or incoherent radiation.

U.S. patent No. 6630301 issued by Gocke et al., revealing the definition of specific extracellular nucleic acids associated with a neoplastic, pre-cancerous or proliferative diseases, including PIN, in fractions of plasma or serum of humans or animals.

In accordance with the content of all available evidence PIN is a possible precursor of adenocarcinoma of the prostate. The clinical significance of treatment PIN based on a clear link PIN with adenocarcinoma of the prostate. Due to limited scientific data, revealing the use of inhibitors SOH-2 the La cancer treatment, the absence of any scientific data regarding the use of inhibitors SOH-2 for the treatment of intraepithelial neoplasia of the prostate, in particular, as a precursor to prostate cancer, it is obvious that there is a huge and urgent need in the treatment of intraepithelial neoplasia of the prostate inhibitors SOH-2. This need is met is presented in the invention methods and compounds that treat intraepithelial the neoplasia of the prostate and significantly reduce or eliminate the development of prostate cancer without significant immediate or delayed side effects such as sexual dysfunction, symptoms of androgen deficiency and gastrointestinal disorders discussed above.

The invention

The present invention relates to a method of treatment of a subject intraepithelial neoplasia of the prostate, comprising the stage of introducing an effective amount of the composition specified subject for treatment or prevention of a specified neoplasia of the prostate gland, and the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger and therapeutically effective amounts of hydroalcoholic ex is rackow Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

In addition, the present invention relates to a method of treatment of the subject has a precancerous cell proliferation in both small and large ducts and acini of the prostate, comprising the stage of introducing an effective amount of the composition specified subject for the treatment or prevention of pre-cancerous cell proliferation, and this composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

Detailed description of the invention

Definition

Used herein, the term "therapeutically effective amount" refers to that amount of the extract, which will contribute to the ability of the composition to cure intraepithelial the neoplasia of the prostate gland.

Used herein, the term "treatment" refers to partial or complete inhibition of growth, proliferation, or metastasis intraepithelial neoplasia of the prostate, and also to partial or complete destruction of the cells having the appearance is characteristic for intraepithelial neoplasia of the prostate gland.

Used herein, the term "prevention" refers to preventing the beginning of intraepithelial neoplasia of the prostate or to the prevention stage intraepithelial neoplasia of the prostate gland that are not detected clinically in subjects at risk. This also implies that this definition covers the prevention of initiation of malignant cells and stops or reverses the progression of pre-malignant cells into malignant. This includes prophylactic treatment of patients at risk for the development of intraepithelial neoplasia of the prostate. In other words, "prevention" also includes the prevention of progression of intraepithelial neoplasia of the prostate in prostate cancer.

Used herein, the term "supercritical gas or supercritical fluid" refers to a gas that is heated to a critical temperature point above which the gas will maintain its gaseous state and will not turn into a liquid regardless of the pressure. Gas heated to a temperature above the critical point, will be very tight under pressure, so that its characteristics resemble those for the fluid, but it will become liquid. Carbon dioxide is typically used in applications requiring a supercritical fluid. General the properties of supercritical fluids and General application of supercritical fluids in the extraction processes described, for example, in Taylor, Supercritical Fluid Extraction, Wiley, 1996; McHugh and Krukonis, Supercritical Fluid Extraction: Principles and Practice, 2nd ed., Butterworth-Heinemann, 1994; Williams and Clifford, Supercritical Fluid Methods and Protocols, Humana Press, 2000, the contents of which are incorporated here by reference.

Used herein, the term "supercritical extraction" refers to the way in which hydrophobic substances can be extracted from the samples using supercritical fluid. The solvent power of the supercritical fluid increases as the pressure and temperature are increased above their critical points, which produces an effective solvent for separation of hydrophobic molecules.

Used herein, the term "hydroalcoholic extraction" refers to the way in which hydrophilic compounds can be extracted from the sample using a solution of alcohol and water, followed by evaporation of the solution with the production of the extract, consisting of dissolved solids.

Used herein, the term "intraepithelial neoplasia of the prostate", or "PIN"refers in a broad sense to the condition of the prostate gland characterized by progressive impairments of phenotype and genotype, which are intermediate between normal epithelium of the prostate and cancer, indicating the weakening of cell differentiation and regulatory control. PIN Rel is referring to possible precancerous final continuous proliferation of cells in the lining of the large and small ducts and acini of the prostate. It is characterized by cellular proliferatum in preexisting ducts and acini with cytological changes that mimic a malignant tumor, with profiles of neoplasia, including enlargement of nuclei and nucleoli, but without invasion into the stroma.

Used herein, the term "subject" refers to any entity, person or mammal, suffering from a neoplasia of the prostate gland, it is preferable to subject-person. The methods of the invention, the subject is any subject, human or animal, preferably the subject is a person who is at risk of developing neoplasia prostate cancer derived from epithelial cells. The subject may include at risk due to exposure to carcinogenic agents, being genetically predisposed to having neoplasia of the prostate, etc.

Used herein, the term "inhibitor of cyclooxygenase-2, or COX-2 inhibitor"refers to a compound or composition capable of inhibiting cyclooxygenase without unwanted inhibition of cyclooxygenase-1.

Treatment of intraepithelial neoplasia of the prostate

Prostate cancer is one of the most common malignant diseases diagnosed in men, and the most common type of cancer of the men older than 60 years. One third of all men over age 50 have a latent form of prostate cancer which can lead to a life threatening prostate cancer. It is shown that intraepithelial neoplasia of the prostate gland is damaged, previous cancer of the prostate.

Intraepithelial neoplasia of the prostate is considered to be in science likely preinvasive stage adenocarcinoma of the prostate. Most studies suggest that most patients with PIN eventually develop cancer. Some studies have shown that between half and two thirds of patients diagnosed with PIN get cancer within 2-3 years. PIN clearly predicts adenocarcinoma, therefore, it is expected that effective treatment PIN should reduce, slow down or eliminate further development of adenocarcinoma of the prostate. In case of detection of cancer at an early or latent stage, the inventors expect that the neoplastic process is reversible or more easily curable. Thus, there is a huge need for effective treatment of the PIN in order to reduce or prevent the development of prostate cancer, the need satisfied by the introduction of the compounds according to the invention.

With the progression PIN in cancer associated increased angiogenesis with led is the increase in the number of microvessels. Microvessels when the PIN is shorter than in benign epithelium, have volatile circuit and an open lumen, increased the number of endothelial cells and greater distance from the basal membrane. Not based on any particular theory of action, the inventors expect that antiangiogenesis properties of the compounds according to the invention will be at least partially cause the reduction or elimination of cells PIN from the subject and, thus, to effectively treat a PIN.

To the extent that they are applied modern methods of treatment PIN include antiandrogenna therapy and radiation therapy. Antiandrogenna therapy has some potential complications, including problems with sexual function, osteoporosis, and reduced muscle mass. Radiation therapy has possible complications, including loss of appetite, weakness, skin reactions such as redness and irritation, a burning sensation in the rectum or damage, diarrhea, cystitis and hematuria. Thus, there is a significant need for effective methods of treatment of intraepithelial neoplasia of the prostate gland, which do not cause severe and often severe side effects typical of previous treatment methods.

Three major isoforms of cyclooxygenase are COX-1, COX-2 and COX-3, and e and the enzymes responsible for the production of a group of eicosanoids, prostaglandins. Isoform COX-1 has a lot of important control functions in the cell and therefore is produced in all cells of the body. However, COX-2 is usually absent in the cell until is induced by specific stimuli. Consequently, it is not surprising that COX-2 is involved in the development of many disease States including cancer. Detected the presence of increased levels of COX-2 in various types of cancer, including cancers of the lung, breast, pancreas, head and neck, skin, glioblastoma and prostate cancer. As discussed above, COX-3 discovered relatively recently, and its relation to cancer, if it exists, is not yet defined.

In respect of intraepithelial neoplasia of the prostate shown that elevated levels of COX-2 are present in some tumor samples and marked increase in the degree of expression of the enzyme COX-2 with progression of the disease. The activity of COX-2 and related products prostaglandins are also involved in induced tumor angiogenesis, which is expected by the inventors, is mediated by specific COX-2 inhibitors. In addition, the inventors expect that certain COX-2 inhibitors cause re-initiation pathways of apoptosis, overcoming factors antiapoptosis processes that are excreted precancerous cells intraepithelial neoplasia of the prostate W is Lesa and leading to cell death.

The authors have developed a mixture of herbal extracts, and this mixture has inhibitory activity against COX-2. Composition, developed by the authors, the unique composition of herbs, their combination and value, synergy and activity of herbs, as well as in connection with obtaining them by supercritical CO2the extraction. Unlike traditional methods of extraction, based on the dissolution of supercritical CO2extraction allows to obtain natural products contained in herbs, without loss of chemicals in the cooking process.

Unexpectedly, in addition to anti-inflammatory action, is described in U.S. patent No. 6387416, the inventors have found that the use of compositions and methods according to the invention causes the inhibition of COX-2 and antineoplastics activity in cell lines intraepithelial neoplasia of the prostate. The inventors also expected that the methods of the invention induce apoptosis and inhibit cell growth of cells in intraepithelial neoplasia of the prostate gland, which deactivates the path of apoptosis.

The method according to the invention based on the discovery that a combination of certain herbs, properly extracted and blended in certain proportions, can be used in cured and intraepithelial neoplasia of the prostate. Thus, the present method according to the invention relates to a method for the treatment of intraepithelial neoplasia of the prostate in a subject, comprising the stage of introducing an effective amount of the composition specified subject for treatment or prevention of a specified intraepithelial neoplasia of the prostate where the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

In one aspect of the specified composition is administered orally.

In another preferred implementation of the input oral composition is applied in the form of one or more capsules, one or more tablets or one or more pills.

In another aspect, the composition includes:

(A) from about 4.5% to 7.5%and more preferably from about 5.5% to about 6.5% by weight of the hydroalcoholic extract of ginger;

(B) from about 5.5% to 8.5%, and more preferably from about 6% to 8% by weight of the supercritical extract of ginger;

(C) from about 1.0% to 1.5%, and more preferably from about 1.2% to 1.4% by weight of the supercritical extract of turmeric;

(D) from about 10.0% to 16.0%of, and more p is edocfile about 11.5% to 14.5% by weight of the supercritical extract of rosemary;

(E) from about 4.0 percent to 6.0%, and more preferably approximately from 4.5% to 5.5% by weight of the supercritical extract of oregano;

(F) from about 10.0% to 16.0%of, and more preferably about 11.5% to 14.5% by weight of the hydroalcoholic extract of turmeric;

(G) about 5.5% to 8.0%, and more preferably from about 6.0% to 7.0 percent by weight of the hydroalcoholic extract of rosemary;

(H) from about 10.0% to 16.0%of, and more preferably about 11.5% to 14.5% by weight of the hydroalcoholic extract of the Basilica of the sacred;

(I) from about 10.0% to 16.0%of, and more preferably about 11.5% to 14.5% by weight of the hydroalcoholic extract of green tea;

(J) from about 8.0% to 12.0 percent, and more preferably approximately from 9.0% to 11.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum;

(K) from about 4.0 percent to 6.0%, and more preferably approximately from 4.5% to 5.5% by weight of the hydroalcoholic extract of coptis Chinese;

(L) from about 4.0 percent to 6.0%, and more preferably approximately from 4.5% to 5.5% by weight of the hydroalcoholic extract of barberry;

(M) from about 2.0% to 3.0 percent, and more preferably approximately from 2.25% to 2.75% by weight of the hydroalcoholic extract of Scutellaria baicalensis.

The hydroalcoholic extract of ginger used in the present invention, it is preferable to obtain the following way. The rhizome of ginger, shredded preferably cryogenic to protect the feelings of the tion to heat components, subjected to supercritical extraction to obtain: (i) extract in the form of oil, here called "supercritical extract, ginger contains volatile lipophilic components, and (ii) do not contain oil residue. Does not contain oil residue then extracted in a mixture of water/alcohol, preferably water/ethanol containing 60 to 80 parts of alcohol and 40-20 parts of water. A solution of the alcohol/water is then evaporated, leaving a powdery residue of the extract, called here "the hydroalcoholic extract of ginger.

In a preferred embodiment, the mass ratio of the supercritical extract of ginger to the hydroalcoholic extract of ginger should be approximately from 0.9:1 to 1.4:1.

Supercritical extracts of ginger, rosemary, turmeric and oregano used in the invention can be obtained in accordance with known methods, supercritical extraction, as described, for example, in E.Stahl, K.W.Quirin, D.Gerard, Dense Gases for Extraction and Refining, Springer Verlag 4 1988, incorporated herein by reference.

Hydroalcoholic extracts of rosemary, turmeric, Basilica of the sacred, Polygonum cuspidatum, coptis Chinese, barberry and Scutellaria baicalensis used in the invention can be obtained in accordance with generally accepted ways hydroalcoholic extraction. For example, the hydroalcoholic extracts can be obtained by extracting portions of the plants in mesivta/alcohol, preferably water/ethanol containing 60 to 80 parts of alcohol and 40-20 parts of water, and then by evaporation of a solution of the alcohol/water, leaving powdery residue of the extract, called here "the hydroalcoholic extract". The hydroalcoholic extract of green tea used in the present invention, is produced by extracting portions of the plants in a mixture of water/alcohol, preferably water/ethanol, and then by evaporation of a solution of the alcohol/water at a temperature ≤80°C, preferably using the method of drying by atomization, leaving powdery residue of the extract.

In another aspect, the mass ratio of the hydroalcoholic extract of turmeric to the supercritical extract of turmeric ranges from about 8:1 to 12:1.

In another aspect, the mass ratio of the supercritical extract of rosemary to the hydroalcoholic extract of rosemary is about 1.6:1 to 2.4:1.

In another aspect of the hydroalcoholic extract of ginger contains approximately from 2.4% to 3.6%, more preferably from about 2.7% to 3.3% and most preferably about 3.0 percent burning substances by weight.

In another aspect of the supercritical extract of ginger contains from about 24% to 36%, more preferably from about 27% to 33%, and most preferably about 30% pungent substances by weight; and from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8% and is, most preferably about 8% zingiberene mass.

In another aspect of the supercritical extract of turmeric contains from about 36% to 54%, more preferably from about 40.5 percent to 49.5%, and most preferably about 45% of turmerone mass.

In another aspect of supercritical rosemary extract contains approximately 18.4% to 27.6%, more preferably about from 20.7% to 25.3%, and most preferably about 23% total phenolic antioxidants by weight.

In another aspect of the supercritical extract of oregano contains from about 0.64% to 0.96%, and more preferably approximately from 0.72% to 0.88% and most preferably about 0.8% total phenolic antioxidants by weight.

In another aspect of the hydroalcoholic extract of turmeric contains from about 5.6% to 8.4%, and more preferably from about 6.3% to 7.7% and most preferably about 7% curcumin by weight.

In another aspect of the hydroalcoholic extract of rosemary contains approximately 18.4% to 27.6%, more preferably about from 20.7% to 25.3%, and most preferably about 23% total phenolic antioxidants by weight.

In another implementation of the hydroalcoholic extract of the Basilica of the sacred contains approximately from 1.6% to 2.4%, more preferably from about 1.8% to 2.2% and most preferably about 2% of ursolic acid by mass.

In another aspect of the hydroalcoholic extract of green tea contains approximately 36%to 54%, more preferably from about 40.5 percent to 49.5%, and most preferably about 45% polyphenols by weight.

In another aspect of the hydroalcoholic extract of Polygonum cuspidatum contains from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8% and most preferably about 8% resveratrol by mass.

In another implementation of the hydroalcoholic extract of coptis Chinese contains from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6% and most preferably about 6% berberine on weight.

In another aspect of the hydroalcoholic extract of barberry contains from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6% and most preferably about 6% berberine on weight.

In another aspect, this composition contains:

(A) from about 4.5% to 7.5 percent by weight of the hydroalcoholic extract of ginger, where the extract contains about 2.4% to about 3.6% by weight of pungent substances;

(B) from about 5.5% to about 8.5 percent by weight of the supercritical extract of ginger, where the extract contains from about 24% to 36% by weight of pungent substances and from about 6.4% to about 9.6% zingiberene by weight;

(C) about 1.0% to 1.5% by weight of the supercritical extract of turmeric, where the extract contains from about 36% to 54% of turmerone by weight;

(D) from about 10.0% to 16.0% of the weight of the supercritical extract of rosemary, where the extract contains about is 18,4% to 27.6% total phenolic antioxidants by weight;

(E) from about 4.0 percent to 6.0% by weight of the supercritical extract of oregano, where the extract contains from about 0.64% to 0.96% for total phenolic antioxidants by weight;

(F) from about 10.0% to 16.0% of by weight of the hydroalcoholic extract of turmeric, where the extract contains from about 5.6% to 8.4% of curcumin by weight;

(G) from about 5.5% to 8.0 per cent by weight of the hydroalcoholic extract of rosemary, where the extract contains from about 18.4% to 27.6% of the total phenolic antioxidants by weight;

(H) from about 10.0% to 16.0% of by weight of the hydroalcoholic extract of the Basilica of the sacred, where the extract contains approximately from 1.6% to 2.4% of ursolic acid by weight;

(I) from about 10.0% to 16.0% of by weight of the hydroalcoholic extract of green tea, where the extract contains from about 36% to 54% polyphenols by weight;

(J) from about 8.0% to 12.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum, where the extract contains from about 6.4% to about 9.6% resveratrol by weight;

(K) from about 4.0 percent to 6.0% by weight of the hydroalcoholic extract of coptis Chinese, where the extract contains from about 4.8% to about 7.2% of berberine by weight;

(L) from about 4.0 percent to 6.0% by weight of the hydroalcoholic extract of barberry, where the extract contains from about 4.8% to about 7.2% of berberine by weight;

(M) from about 2.0% to 3.0 percent by weight of the hydroalcoholic extract of Scutellaria baicalensis;

where the specified composition additionally contains:

(i) verhnechonsky ginger extract and hydroalcoholic extract of ginger with a weight ratio of from about 0.9 to 1.4 parts supercritical extract to 1 part postsurgical;

(ii) the hydroalcoholic extract of turmeric and supercritical extract of turmeric powder with a weight ratio of from about 8 to 12 parts of a hydroalcoholic extract per 1 part of supercritical extract;

(iii) supercritical rosemary extract and hydroalcoholic extract of rosemary with weight ratio of from about 1.6 to 2.4 parts supercritical extract per 1 part of the hydroalcoholic extract.

In a preferred implementation, the composition is administered in a daily dose of at least 700 mg

In another aspect the composition is administered for at least 4 weeks with daily admission.

In a further embodiment according to the invention is a method of treating pre-cancerous cell proliferation in prostatic ducts, small ducts and acini of the subject includes a stage of introducing an effective amount of the composition specified subject for treatment or prevention of the specified pre-cancerous cell proliferation, where the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

The advantage of the compositions according to the invention is used in isawanya supercritical extraction, innovative technologies for the extraction of herbs at low temperature without the use of industrial chemical solvents. This extraction process allows us to achieve high efficiency of the active components in the extracts, 250 times the effectiveness of natural fresh plant material.

The table presents the preferred composition for oral administration, excluding inactive ingredients, as it was used in the method according to the invention. The number shown in the table represent the preferred dose of the described ingredients.

GrassThe type of extractPart of the plantAmount (mg)
Rosemarysupercriticalsheet100
Rosemaryalcohol (23% TRA of 34.5 mg)sheet50
Turmericsupercritical (45% of turmerone - 4.5 mg)rhizome10
Turmericalcohol (7% curcumin - 7 mg)rhizome100
Gingersupercritical (30% pungent compounds - 16.2 mg, 8% of zingiberene - 4.3 mg)rhizome54
Gingeralcohol (3% pungent compounds - 1.4 mg)rhizome46
Holy Basilalcohol (2% orsolino acid - 2 mg)sheet100
Green teaalcohol (45% polyphenols - 45 mg)sheet100
Polygonum cuspidatum- alcohol (8% resveratrol - 6.4 mg)the root and rhizome80
Coptis Chinesealcohol (6% berberine - 2.4 mg)root40
Barberryalcohol (6% berberine -2,4 mg) root40
Oreganosupercritical (0,8% TRA - 0,32 mg)sheet40
Scutellaria baicalensis- alcohol (5:1)root20

Preferably, the composition shown in the table, also included olive oil extracity and yellow beeswax.

The methods according to the invention is used therapeutically effective amount of the active components mentioned above. These effective amounts should generally contain from about 0.1 mg to 100 mg of active agent per kilogram body weight of the patient per day. This effective amount can vary depending on the physical condition of the patient, and other factors well known to science. Moreover, it should be clear that these doses of active agents can be administered in single or split the dosage to achieve the desired therapeutic effect. Optionally, other therapeutic agents may be used in combination with the compounds according to the invention.

The methods according to the invention using the composition, which preferably are introduced to patients using the receiving conventional pharmaceutical carriers. Such carriers are well known to specialists in this field and, in General, can be in solid or liquid form. Solid forms of pharmaceutical preparations which can be obtained in accordance with the method according to the invention include powders, tablets, dispersible granules, capsules and pills. In General, solid form preparations may contain from about 5% to 90% active agent by weight.

A solid carrier can be one or more substances which may also act as solvents, flavorings, solubilization, lubricants, suspendida agents, binders or dezintegriruetsja tablets agents; it can also serve as a material for capsules. In powders, as a rule, use solid granular media in a mixture with the active viscous component. In tablets, the active component is mixed in appropriate proportions with the carrier having the necessary binding properties, and give the mixture the desired shape and size. Acceptable solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragakant, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter and similar compounds. The term "obtaining" includes the preparation of the composition of the active component encapsulates m the material as a carrier, which is used for formation of capsules in which the active component (with another carrier or not) is surrounded by media and is, thus, in interaction with him. Also includes a wafer. Tablets, powders, pills and capsules can be used as solid dosage forms suitable for oral administration. If required for reasons of convenience or at the request of the patient, pharmaceutical tablets obtained in accordance with the method according to the invention, can be manufactured in the form of chewing tablets using methods well known to specialists in this field.

Also considered acceptable carriers solid forms of the drug that can be converted immediately prior to use in liquid forms for oral and parenteral use. Such liquid forms include solutions, suspensions and emulsions. These solid forms of drugs most convenient for dosing and as such are used for the preparation of individual liquid doses of the drug. On the other hand, a convenient solid form can be used so that after transformation into liquid form can be obtained from several individual liquid doses by measuring the specific volumes of the liquid form of the drug with a syringe, can the th spoon or other measuring volume. When multiple liquid doses obtained in this way, it is desirable to store the unused portion of the above liquid doses at low temperature (e.g. in a refrigerator) in order to avoid possible decomposition. Solid forms of the drug, intended to become the liquid form may contain, in addition to the active material fragrances, dyes, stabilizers, buffers, artificial and natural sweeteners, dispersing agents, thickeners, wetting and similar compounds. The liquid used to obtain a desired liquid forms of the drug may be water, isotonic water, ethanol, glycerin, propylene glycol and similar compounds as well as mixtures thereof. Naturally, the liquid used should be selected in accordance with the method of application. For example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.

The pharmaceutical preparation can also be presented in unit dosage form. In such form the preparation is divided into unit doses containing certain quantities of the active component. The unit dosage form can be a packaged preparation, the package containing various amounts of the drug, such as packaging of tablets, capsules, and powders in vials or ampoules. Unit d is tirovannoj form can also be itself capsule, a wafer or tablet, or it may be a certain number of them in Packed form.

The pharmaceutical preparations according to the invention may include one or more preservatives, is well known to specialists in this field, such as benzoic acid, sorbic acid, methylparaben, propylparaben, and ethylenediaminetetraacetic acid (EDTA). Preservatives are usually present in amounts up to 1% and preferably from about 0.05 to 0.5% by weight of the pharmaceutical compounds.

Applicable buffers for compounds according to the invention include citric acid-sodium citrate, phosphoric acid-sodium phosphate and acetic acid-sodium acetate in amounts up to 1% and preferably from about 0.05 to 0.5% by weight of the pharmaceutical compounds. Applicable suspendresume agents or thickeners include products of cellulose, such as methylcellulose, carragenan, such as alginic acid and its derivatives, xanthan resin, gelatin, gum and microcrystalline cellulose in amounts up to 20% and preferably from about 1% to 15% by weight of the pharmaceutical compounds.

Sweeteners that can be used, include both artificial and natural sweeteners, well known to specialists in this field. Sweeteners such as monosaccharides, disaccharides the polysaccharides, such as xylose, ribose, glucose, mannose, galactose, fructose, dextrose, sucrose, maltose, partially hydrolyzed starch or dry corn syrup, and sugar alcohols such as sorbitol, xylitol, mannitol and mixtures thereof, can be used in amounts from about 10% to 60% and preferably from about 20% to 50% by weight of the pharmaceutical compounds. Water-soluble artificial sweeteners such as saccharin and salts of saccharin, such as sodium or calcium, salts of cyclamate, Acesulfame-K, aspartame and the like, and mixtures thereof can be used in amounts of about from 0.001% to 5% by weight of the pharmaceutical compounds.

Flavorings that can be used in pharmaceutical products according to the invention include both natural and artificial flavors, mint, such as peppermint, menthol, vanilla, artificial vanilla, chocolate, artificial chocolate, cinnamon, various fruit flavors separately, or blended and used in amounts from about 0.5% to 5% by weight of the pharmaceutical compounds.

Dyes that may be used according to the invention include pigments which may be added in amounts up to 6% of the weight of the connection. The preferred pigment, titanium dioxide, may be added in amounts up to 1%. Also krassi the eating can include other colorants, suitable for food, drug or cosmetic use, known as F.D.&C. dyes, and the like. Such dyes are generally present in amounts up to 0.25%, and preferably about from 0.05% to 0.2% by weight of the pharmaceutical compounds. A complete list of all F.D.&C. and D.& C. colorants and their corresponding chemical structures may be found in Kirk-Othmer Encyclopedia of Chemical Technology, v. 5, PP. 857-884, which text is given here as a reference.

Applicable solvents include alcohol, propylene glycol, polyethylene glycol and the like and can be used for dissolution of flavors. Dissolving agents are usually present in amounts up to 10% and preferably from about 2% to 5% by weight of the pharmaceutical compounds.

Lubricants that can be used if necessary in the soluble compounds include silicone oils or fluids, such as substituted and unsubstituted polysiloxane, such as dimethylpolysiloxane, also known as Dimethicone. Can be used and other well-known lubricants.

It is not expected that the compounds used in the methods according to the invention will exhibit undesirable interactions with other synthetic or natural substances. As a consequence, the connection according to the invention can be used in combination with the other compounds and substances, necessary for the treatment of intraepithelial neoplasia of the prostate. In particular, the compounds used in the methods according to the invention can be administered in combination with other compounds according to the invention, other antineoplastics substances and the like.

The optimal pharmaceutical recipe can be determined by an expert in the field of science, depending on circumstances such as the method of application and the required dose. See, for example, "Remington''s Pharmaceutical Sciences, 18thed. (1990, Mack Publishing Co., Easton, PA 18042), pp.1435-1712, which is given here in full as a reference. Such recipes can influence the physical state, stability, degree of liberation in vivo and the degree of clearance in vivo therapeutic agents according to the invention.

Method(s) of introduction

Substances and compositions mainly administered orally in the form of capsules, tablets, aqueous suspensions or solutions. Tablets may contain carriers, such as lactose and corn starch, and/or lubricants such as magnesium stearate. Capsules may contain diluents, including lactose and dried corn starch. Aqueous suspensions can contain emulsifying and suspendresume agents in combination with the active ingredient. Forms for oral administration may also contain sweetening, flavoring, coloring agents or their Kombinat is I. Pill use, drips or capsules, coated enteric, to increase stability and release in the intestinal tract to improve the suction is the best way of introduction, currently under consideration.

Dosage

Dosing levels in the range from about 0.001 mg to 100 mg of the active ingredient substances or compounds per kilogram of body weight applicable to the treatment under the above conditions, with preferred levels dosage range from 200 mg / day to 1600 mg per day. Substances and compositions according to the invention may generally be administered in two or three doses daily. The preferred strategy is to initiate treatment with low doses (200-300 mg) twice a day and slowly increase the dose, if necessary. The amount of active ingredient that may be associated with materials native to a unit dosage form may vary depending on the patient and the specific conditions of use.

It is clear, however, that the specific dose level for each individual patient will depend on many factors, including the activity of the used specific substances; the age, body weight, General health, sex and diet of the patient; the time of administration; the degree of excretion, combination Lakers is in; the severity of disorders to be treated; and the form of administration. Specialist in this field should take into account the diversity of these factors and are able to set specific levels of dosage, without resorting to complex survey methods.

Examples

The following examples are an illustration of the method according to the invention and does not pretend to be limiting factors for him. Unless otherwise specified, all percentages are based on 100% by weight of the final connection.

Example 1

Obtaining compositions according to the invention

The composition of the invention is produced by way of well-known experts in the field of science and described in application for U.S. patent No. 6387416. The contents of U.S. patent No. 6387416 incorporated herein by reference in full. Obtaining the constituent elements of the composition according to the invention is summarized in the following.

The hydroalcoholic extract of ginger used in the composition according to the invention is preferably prepared as follows. Ginger rhizome, which is preferably crushed for cryogenic preservation resistant to heat components, is subjected to supercritical extraction to obtain: (i) extract in the form of oil, here called "supercritical extract, ginger contains volatile lipophilic components, and (ii) do not contain oil residue. Does not contain oil residue then ex is reginout in a mixture of water/alcohol, preferably water/ethanol containing 60 to 80 parts of alcohol and 40-20 parts of water. A solution of the alcohol/water is then evaporated, leaving a powdery residue of the extract, called here "the hydroalcoholic extract of ginger.

The composition according to the invention should preferably contain supercritical ginger extract and hydroalcoholic extract of ginger at a weight ratio of from about 0.9 to 1.4 parts, more preferably from about 1.1 to 1.3 parts, most preferably about 1.17 parts of the supercritical extract of ginger to 1 part of the hydroalcoholic extract of ginger.

Supercritical extracts of ginger, rosemary, turmeric and oregano used in the compositions according to the invention, can be obtained in accordance with known methods, supercritical extraction, as described, for example, in E.Stahl, K.W.Quirin, D.Gerard, Dense Gases for Extraction and Refining, Springer Verlag 4 1988, incorporated herein by reference.

Hydroalcoholic extracts of rosemary, turmeric, Basilica of the sacred, Polygonum cuspidatum, coptis Chinese, barberry and Scutellaria baicalensis used in the compositions according to the invention, can be obtained in accordance with generally accepted ways hydroalcoholic extraction. For example, the hydroalcoholic extracts can be obtained by extracting portions of the plants in a mixture of water/alcohol, preferably water/ethanol, preferably the content is soup 60-80 parts of alcohol and 40-20 parts of water, and then evaporation of a solution of the alcohol/water, leaving powdery residue extract (called here "the hydroalcoholic extract"). The hydroalcoholic extract of green tea used in the present invention, is produced by extracting portions of the plants in a mixture of water/alcohol, preferably water/ethanol, and then by evaporation of a solution of the alcohol/water at a temperature ≤80°C, preferably using the method of drying by atomization, receiving powdered residue of the extract.

In the composition according to the invention the hydroalcoholic extract of turmeric and supercritical extract of turmeric should preferably be contained in a weight ratio of from about 8 to 12 parts, more preferably from about 9 to 11 parts, most preferably about 10 parts of a hydroalcoholic extract to 1 part of supercritical extract.

The composition according to the invention should preferably contain supercritical rosemary extract and hydroalcoholic extract of rosemary in a weight ratio of from about 1.6 to 2.4 parts, more preferably from about 1.8 to 2.2 parts, most preferably about 2.0 parts supercritical extract to 1 part of the hydroalcoholic extract.

The hydroalcoholic extract of ginger used in the composition according to the invention should preferably contain from about 2.4% to 3.6%, the more edocfile from about 2.7% to 3.3% and most preferably about 3.0 percent burning substances by weight (for example, shogaol).

Supercritical extract of ginger used in the composition according to the invention should preferably contain from about 24% to 36%, more preferably from about 27% to 33%, and most preferably about 30% pungent substances by weight (for example, shogaol) and preferably from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8% and most preferably about 8% zingiberene mass.

Supercritical extract of turmeric used in the composition according to the invention should preferably contain from about 36% to 54%, more preferably from about 40.5 percent to 49.5%, and most preferably about 45% of turmerone mass.

Supercritical rosemary extract used in the compositions according to the invention should preferably contain from about 18.4% to 27.6%and, more preferably approximately from 20.7% to 25.3%, and most preferably about 23% total phenolic antioxidants ("TRA") on weight.

Supercritical extract of oregano used in the composition according to the invention should preferably contain from about 0.64% to 0.96%, and more preferably approximately from 0.72% to 0.88% and most preferably about 0.8% TRA mass.

The hydroalcoholic extract of turmeric used in the composition according to the invention should preferably contain from about 5.6% to 8.4%, and more preferred is sustained fashion from about 6.3% to 7.7% and most preferably about 7% curcumin by weight.

The hydroalcoholic extract of rosemary used in the composition according to the invention should preferably contain from about 18.4% to 27.6%and, more preferably approximately from 20.7% to 25.3%, and most preferably about 23% TRA mass.

The hydroalcoholic extract of the Basilica of the sacred, used in the composition according to the invention should preferably contain from about 1.6% to 2.4 percent, more preferably from about 1.8% to 2.2% and most preferably about 2% of ursolic acid by mass.

The hydroalcoholic extract of green tea used in the composition according to the invention should preferably contain from about 36% to 54%, more preferably from about 40.5 percent to 49.5%, and most preferably about 45% polyphenols by weight.

Hydroalcoholic extract of Polygonum cuspidatum used in the composition according to the invention should preferably contain from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8% and most preferably about 8% resveratrol by mass.

Vodnospirtova extract coptis Chinese, used in the composition according to the invention should preferably contain from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6% and most preferably about 6% berberine on weight.

The hydroalcoholic extract of barberry used in the compositions of izaberete the Oia, should preferably contain from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6% and most preferably about 6% berberine on weight.

Example 2

The action of the compositions according to the invention for precancerous intraepithelial the neoplasia of the prostate

It seems the patient for the treatment of precancerous intraepithelial neoplasia of the prostate. The composition according to the invention is administered to a specified patient treatment in a few weeks, during which they observed significant side effects. The patient was observed reversion of growth of pre-neoplastic cells and the death of the available pre-neoplastic cells, resulting in intraepithelial neoplasia of the prostate ceased to be. With continued treatment, the patient has no secondary symptoms intraepithelial neoplasia of the prostate and delayed side effects of treatment and did not develop prostate cancer.

It is obvious that the described thus the method according to the invention can be modified or changed in many ways. Such modifications and variations are not considered as a deviation from the essence and scope of the invention, and assumes that all such modifications and variations are included in the scope of the following claims.

1. The method of treatment is the subject of intraepithelial neoplasia of the prostate, includes the stage of introduction of a specified subject an effective amount of a composition for the treatment of specified intraepithelial neoplasia of the prostate gland, and the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

2. The method according to claim 1, in which the above composition is administered orally.

3. The method according to claim 2, in which the composition for oral administration are presented in the form of one or more capsules, one or more tablets, or one or more pills.

4. The method according to claim 1, wherein the composition comprises: (A) from about 4.5 to 7.5% by weight of aqueous-alcoholic extract of ginger;
(B) from about 5.5 to 8.5% by weight of the supercritical extract of ginger;
(C) from about 1.0 to 1.5% by weight of the supercritical extract of turmeric;
(D) from about 10.0 to 16.0% of the weight of the supercritical extract of rosemary;
(E) from about 4.0 to 6.0 percent by weight of the supercritical extract of oregano;
(F) from about 10.0 to 16.0% of the weight of the hydroalcoholic extract of turmeric;
(G) about 5.5 to 8.0% by mass of aqueous-alcoholic extract of rosemary;
(H) from about 0.0 to 16.0% by weight of a water-alcohol extract of the Basilica of the sacred;
(I) from about 10.0 to 16.0% of the weight of the hydroalcoholic extract of green tea;
(J) about from 8.0 to 12.0 mass% of water-alcohol extract of Polygonum cuspidatum;
(C) from about 4.0 to 6.0 percent by weight of aqueous-alcoholic extract of coptis Chinese;
(L) from about 4.0 to 6.0 percent by weight of aqueous-alcoholic extract of barberry; and
(M) from about 2.0 to 3.0 percent by weight of aqueous-alcoholic extract of Scutellaria baicalensis.

5. The method according to claim 1, wherein the mass ratio of the supercritical extract of ginger to the water-alcohol extract of ginger is approximately from 0.9:1 to 1.4:1.

6. The method according to claim 1, wherein the mass ratio of the water-alcohol extract of turmeric to the supercritical extract of turmeric ranges from about 8:1 to 12:1.

7. The method according to claim 1, wherein the mass ratio of the supercritical extract of rosemary to the water-alcohol extract of rosemary is about 1.6:1 to 2.4:1.

8. The method according to claim 1 in which the aqueous-alcoholic extract of ginger is from about 2.4 to 3.6 per cent by weight of pungent compounds.

9. The method according to claim 1, in which the supercritical extract of ginger contains approximately 24 to 36% by weight of pungent compounds and from about 6.4 to 9.6 percent by weight of zingiberene.

10. The method according to claim 1, in which the supercritical extract of turmeric contains from about 36 to 54% by weight of turmerone.

11. The method according to claim 1, in which supercritical extract Rosma the ina contains approximately 18.4 27.6% by weight of all phenolic antioxidants.

12. The method according to claim 1, in which the supercritical extract of oregano contains approximately from 0.64 to 0.96% by weight of all phenolic antioxidants.

13. The method according to claim 1, wherein the water-alcohol extract of turmeric contains from about 5.6 to 8.4 per cent by weight of curcumin.

14. The method according to claim 1, wherein the water-alcohol extract of rosemary contains approximately 18.4 27.6% by weight of all phenolic antioxidants.

15. The method according to claim 1 in which the aqueous alcoholic extract of the Basilica of the sacred contains approximately from 1.6 to 2.4% by weight of ursolic acid.

16. The method according to claim 1, wherein the water-alcohol extract of green tea contains about 36 to 54% by weight of polyphenols.

17. The method according to claim 1 in which the aqueous-alcoholic extract of Polygonum cuspidatum contains from about 6.4 to 9.6 percent by weight of resveratrol.

18. The method according to claim 1, wherein the water-alcohol extract of coptis Chinese contains from about 4.8 to 7.2 per cent by weight of berberine.

19. The method according to claim 1, in which the hydroalcoholic extract of barberry contains from about 4.8 to 7.2 per cent by weight of berberine.

20. The method according to claim 1, in which the specified composition comprises:
(A) from about 4.5 to 7.5% by weight of aqueous-alcoholic extract of ginger, where the extract comprises from about 2.4 to 3.6 per cent by weight of pungent compounds;
(B) from about 5.5 to 8.5% by weight of the supercritical extract of ginger, where the extract contains from about 24 to 36% in mA is CE pungent compounds and from about 6.4 to 9.6 percent by weight of zingiberene;
(C) from about 1.0 to 1.5% by weight of the supercritical extract of turmeric, where the extract contains from about 36 to 54% by weight of turmerone;
(D) from about 10.0 to 16.0% of the weight of the supercritical extract of rosemary, where the extract contains approximately 18.4 27.6% by weight of all phenolic antioxidants;
(E) from about 4.0 to 6.0 percent by weight of the supercritical extract of oregano, where the extract contains approximately from 0.64 to 0.96% by weight of all phenolic antioxidants;
(F) from about 10.0 to 16.0% of the weight of the hydroalcoholic extract of turmeric, where the extract contains from about 5.6 to 8.4 per cent by weight of curcumin;
(G) about 5.5 to 8.0% by mass of aqueous-alcoholic extract of rosemary, where the extract contains approximately 18.4 27.6% by weight of all phenolic antioxidants;
(H) from about 10.0 to 16.0% of the weight of the water-alcohol extract of the Basilica of the sacred, where the extract contains approximately from 1.6 to 2.4% by weight of ursolic acid;
(I) from about 10.0 to 16.0% of the weight of the hydroalcoholic extract of green tea, where the extract contains from about 36 to 54% by weight of polyphenols;
(J) about from 8.0 to 12.0 mass% of water-alcohol extract of Polygonum cuspidatum, where the extract contains from about 6.4 to 9.6 percent by weight of resveratrol;
(C) from about 4.0 to 6.0 percent by weight of aqueous-alcoholic extract of coptis Chinese, where the extract contains from about 4.8 to 7.2 per cent by weight of berberine; (L) from about 4.0 to 6.0 percent by weight of aqueous-alcoholic extract of barberry, where the extract contains from about 4.8 to 7.2 per cent by weight of berberine; and
(M) from about 2.0 to 3.0 percent by weight of aqueous-alcoholic extract of Scutellaria baicalensis;
and where the specified composition further comprises:
(i) supercritical ginger extract and hydroalcoholic extract of ginger in a mass ratio of about 0.9 to 1.4 hours supercritical extract 1 tsp water-alcohol extract;
(ii) water / ethanol turmeric extract and supercritical extract of turmeric powder in a mass ratio of about 8 to 12 water-alcohol extract for 1 h supercritical extract; and
(iii) supercritical rosemary extract and hydroalcoholic extract of rosemary in a mass ratio of about 1.6 to 2.4 hours supercritical extract 1 tsp water-alcohol extract.

21. The method according to claim 1, wherein the composition is administered in a daily dose of at least approximately 700 mg.

22. The method according to claim 1, in which the above composition is administered on a daily basis, at least within 4 weeks.

23. The method of treatment of a patient pre-cancerous cell proliferation in both small and large ducts and acini of the prostate, comprising the stage of introduction of a specified subject an effective amount of a composition for the treatment indicated is Anna precancerous cell proliferation, includes the stage of introduction of a specified subject an effective amount of the composition for treatment of the indicated tumor, and this composition contains therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

24. The method according to item 23, in which the above composition is administered orally.

25. The method according to paragraph 24, in which the composition for oral administration are presented in the form of one or more capsules, one or more tablets, or one or more pills.

26. The method according to item 23, in which the composition contains:
(A) from about 4.5 to 7.5% by weight of aqueous-alcoholic extract of ginger;
(B) from about 5.5 to 8.5% by weight of the supercritical extract of ginger;
(C) from about 1.0 to 1.5% by weight of the supercritical extract of turmeric;
(D) from about 10.0 to 16.0% of the weight of the supercritical extract of rosemary;
(E) from about 4.0 to 6.0 percent by weight of the supercritical extract of oregano;
(F) from about 10.0 to 16.0% of the weight of the hydroalcoholic extract of turmeric;
(G) about 5.5 to 8.0% by mass of aqueous-alcoholic extract of rosemary;
(H) from about 10.0 to 16.0% of the weight of the water-alcohol extras the KTA Basilica of the sacred;
(I) from about 10.0 to 16.0% of the weight of the hydroalcoholic extract of green tea;
(J) about from 8.0 to 12.0 mass% of water-alcohol extract of Polygonum cuspidatum;
(C) from about 4.0 to 6.0 percent by weight of aqueous-alcoholic extract of coptis Chinese;
(L) from about 4.0 to 6.0 percent by weight of aqueous-alcoholic extract of barberry; and
(M) from about 2.0 to 3.0 percent by weight of aqueous-alcoholic extract of Scutellaria baicalensis.

27. The method according to item 23, in which the mass ratio of the supercritical extract of ginger to the water-alcohol extract of ginger is approximately from 0.9:1 to 1.4:1.

28. The method according to item 23, in which the mass ratio of the water-alcohol extract of turmeric to the supercritical extract of turmeric ranges from about 8:1 to 12:1.

29. The method according to item 23, in which the mass ratio of the supercritical extract of rosemary to the water-alcohol extract of rosemary is about 1.6:1 to 2.4:1.

30. The method according to item 23, in which the aqueous-alcoholic extract of ginger is from about 2.4 to 3.6 per cent by weight of pungent compounds.

31. The method according to item 23, in which the supercritical extract of ginger contains approximately 24 to 36% by weight of pungent compounds and from about 6.4 to 9.6 percent by weight of zingiberene.

32. The method according to item 23, in which the supercritical extract of turmeric contains from about 36 to 54% by weight of turmerone.

33. The method according to item 23, in which supercritical extrac the rosemary contains approximately 18.4 27.6% by weight of all phenolic antioxidants.

34. The method according to item 23, in which the supercritical extract of oregano contains approximately from 0.64 to 0.96% by weight of all phenolic antioxidants.

35. The method according to item 23, in which the water-alcohol extract of turmeric contains from about 5.6 to 8.4 per cent by weight of curcumin.

36. The method according to item 23, in which the water-alcohol extract of rosemary contains approximately 18.4 27.6% by weight of all phenolic antioxidants.

37. The method according to item 23, in which a water-alcohol extract of the Basilica of the sacred contains approximately from 1.6 to 2.4% by weight of ursolic acid.

38. The method according to item 23, in which the water-alcohol extract of green tea contains about 36 to 54% by weight of polyphenols.

39. The method according to item 23, in which a water-alcohol extract of Polygonum cuspidatum contains from about 6.4 to 9.6 percent by weight of resveratrol.

40. The method according to item 23, in which the water-alcohol extract of coptis Chinese contains from about 4.8 to 7.2 per cent by weight of berberine.

41. The method according to item 23, in which the hydroalcoholic extract of barberry contains from about 4.8 to 7.2 per cent by weight of berberine.

42. The method according to item 23, in which the above composition is administered in a daily dosage, component, at least about 700 mg.

43. The method according to item 23, in which the above composition is administered on a daily basis, at least for 4 weeks.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to oncology, and can be used for optimisation of treatment tactics in case of Hodgkin's lymphoma in children and teenagers. Method is realised in the following way. Such unfavourable prognostic factors as: age over 10 years, IV stage of disease, conglomerate dimensions more than 5 cm and/or value of mediastinal-thoracic index greater than 0.33, number of affected zones more than 4, symptoms of intoxication and biological activity of process. After that three risk groups are determined by the sum of detected unfavourable factors. In the first group, if 0-2 factors are detected, 2 cycles of polychemotherapy in accordance with regimen VBVP are carried out, in the second group, if 3-4 risk factors are detected - 4 cycles in alternating regimen VBVP-ABVD-VBVP-ABVD, in the third group, if 5-6 factors are detected - 6 cycles in alternating regimen VBVP-ABVD-VBVP-ABVD-VBVP-ABVD. Two weeks after carrying out polychemotherapy in all groups irradiation of all earlier affected zones is performed.

EFFECT: method allows to reduce risk of post-cytostatic and radiation complications development due to reduction of treatment loading in patients.

1 tbl, 1 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: new pyrrolotriazine derivatives of general formula (I) are described, where R1 is possibly substituted piperidinyl or piperazinyl; R2 is possibly substituted phenyl; R3 is hydrogen; X is -NH-; Y is -CH2-; as well as their pharmaceutically acceptable salts or steroisomers, and pharmaceutical compositions containing said compounds.

EFFECT: given compounds are kinase inhibitors and can be used in medicine, for example as anticancer agents.

9 cl, 267 ex, 2 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to new derivatives of imidazo[1,2-c]pyrimidinyl acetic acid of formula (I) or to its salts: , where R1 is ,, in which n is an integer ranging from 0 to 6; Y is aryl, where the said aryl is optionally substituted at a substitutable position with one or more substitutes selected from a group which consists of halogen or C1-6alkyl, optionally substituted with mono-, di- or trihalogen; R2 is hydrogen; R3 is hydrogen or halogen; and R4 is hydrogen. The invention also relates to derivatives of imidazo[1,2-c]pyrimidinyl acetic acid of formula (I-i) or to its salts, to a drug, to use of compounds in paragraph 1, as well as to a drug in form of a standard single dosage.

EFFECT: obtaining new biologically active compounds, which are active towards CRTH2.

23 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, oncology, and can be used for thermochemoradiation therapy of oesophagus cancer. That is ensured by local transoesophageal hyperthermia, gamma-ray teletherapy and chemotherapy as preoperative actions. Herewith gamma-ray therapy is carried out within 2 weeks in average fractionation mode at 3 Gy 5 times a week to total focal dose 30 Gy. Chemotherapy accompanies the whole course of gamma therapy by daily introduction of fluorouracil dosed 300 mg/m2 to the central vein in continuous infusion mode and daily intravenous introduction of cisplatin dosed 6 mg/m2 daily within 1 hour. Hyperthermia is applied on 4th, 8th and 12th days of gamma therapy immediately before irradiation session at temperature 42-44°C within 60 minutes.

EFFECT: method allows optimising treatment of the patients suffering from oesophagus cancer and improving clinical effectiveness owing to advanced local control.

3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medical products and covers applications of O- and S-glycosides 5-hydroxy-1,4-naphthoquinone (judlone) derivatives of formula 1 as an agent that stimulates human leukaemia cell apoptosis. Disclosed compounds selectively stimulate human leukemia cell apoptosis as comparrf with a prototype juglone without affecting normal cells of human immune system (neutrophils).

EFFECT: invention allows extending range of products selectively stimulating leukaemia cell apoptosis.

4 cl, 13 dwg, 5 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in chemotherapeutic treatment of locally advanced and general breast cancer. It is ensured by autoplasmochemotherapy. Every time before introduction of cytostatic agents incubated with autoplasma, Trental is introduced intravenously drop-by-drop in a dose 100 mg dissolved in physiologic saline 200 ml.

EFFECT: method improves clinical effectiveness and reduces toxicity of autoplasmochemotherapy due to potentiation of anticancer action of chemoprepatations and protection of blood and bone marrow cells.

2 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely oncology and can be used for neoadjuvant treatments of stomach cancer that is ensured by intraarterial introduction of taxotere 75 mg/m2 and cisplatin 75 mg/m2 with selective catheterisation of celiac trunk. Regional chemotherapy in number of 2 to 4 courses is performed.

EFFECT: application of the invention enables higher operability and clinical effectiveness ensured by downsising of tumour and loc-regional metastases.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine area, namely to oncology, and can be used for treatment of locally advanced non-small cell lung cancer. The therapy involves neoadjuvant chemotherapy, introduction of a radio sensitiser, surgical treatment and intraoperative radiation therapy. The preoperative period involves 2 courses of neoadjuvant chemotherapy with Taxol and carboplatin. Two hours before irradiation, gemcitabine is introduced in a dose 300 mg/m2, then radical operation with intraoperative radiation therapy in a single dose 15 Gy on regional lymphatic cancer spread area is performed.

EFFECT: invention allows improving clinical effectiveness of locally advanced non-small cell lung cancer owing to reduced post-radiation complications and higher survival rate of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmacy, namely to agents for inhibition of development or progression of liver cancer in hepatitis C positive patients suffering from cirrhosis, wherein the agent contains three types of amino acids, namely isoleucine, leucine and valine, wherein mass ratio of isoleucine, leucine and valine makes 1:1.5-2.5:0.8-1.7.

EFFECT: invention provides effective inhibition of development or progression of liver cancer in hepatitis C positive patients suffering from cirrhosis.

18 cl, 1 ex, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to new compounds of formula (I) and pharmaceutically acceptable salts of the said compound, which has c-met kinase inhibitory properties. In general formula (I) W is -N=, and X is hydrogen, Y is hydrogen or A2-R group; A2 is C1-C5alkylene; R is hydroxy; n equals 1, and Z is benzyloxy; or alternatively W is -CH=, and X is hydrogen, OR1; R1 is chosen from A1-Q1group; A1 is 1,2-ethylene or 1,3-propylene group; Q1 is hydroxyl; Y is a A2-R group; A2 is C1-C5alkylene; R is hydroxy; n equals 1, and Z is C1-C3alkoxy, substituted with pyridinyl, and pharmaceutically acceptable salts of the said compound.

EFFECT: can be used for treating cancer and cancer-related diseases.

8 cl, 36 ex

FIELD: medicine.

SUBSTANCE: invention concerns pharmacology and medicine. It involves water-salt extraction of Canadian goldenrod pollen pre-defatted by ethyl ester and dried. Extraction of fat-free and dried Canadian goldenrod pollen is carried out with Evans-Cook liquid during three days with daily agitation at temperature 15-26°C three times for 30-40 minutes every 1-1.5 hours. In intervals between agitations the material is kept at temperature 4-8°C. After extraction, supernatant fluid is poured out that is followed with centrifugation at 5000-6000 rpm within 30-40 minutes and filtration through a paper filter. Then sterilisation filtration, stabilisation of the mother liquor of allergen within 1-3 months and cultivation thereof after finished diagnostic allergen is made.

EFFECT: invention allows making a preparation not causing a sensitisation in animals in a diagnostic dose, possessing specific activity in reaction of indirect degranulation of rat's mast cells.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for prevention of inflammatory processes in animals. That is ensured by putting in a dark glass bottle at the relation g (wt %) of mixed dry powdered elecampane rhizomes and roots - 20.0 (5,9) plaster clover leaves, blossom, fruits, thin bodies - 14.5 (4.4), oak barks - 15.0 (4.4), touch-and-heal herb - 20.0 (5.9), calendula blossom basket - 20.0 (5,9), burnet bloodwort rhizomes and roots - 20.0 (5.9), lavender blossom clusters - 20.0 (5.9), peppermint leaves, bodies and blossom - 20.0 (5.9), costmary blossom baskets - 15.0 (4.4), common plantain leaves - 20.0 (5.9), horse gowan blossom - 20.0 (5.9), common licorice rhizomes, soboles - 20.0 (5.9), nosebleed herb - 20.0 (5.9), thyme herb - 20.0 (5.9), full-maturity hips - 20.0 (5.9), eucalyptus leaves - 20.0 (5.9), killwort leaves, bodies, blossom, fruits - 15.0 (4.4), and nonfrozen stoned sea-buckthorn fruits- 20.0 (5.9). Then agitated mixture is filled with 1500.0 g of corn or sunflower oils either plain or refined, or olive oil either plain or salad. The prepared mixture is kept at room temperature with constant mixing for 25-30 days with following separation of vegetable sediment and preparing of oil-vegetable agent. The prepared vegetable sediment is filled with 1500.0 g of 0.9% sterile solution of table salt at temperature no more than 50 C, and kept in agitation for 25-30 days to produce thereby an aqueous-vegetable agent. For each 100.0 g of prepared oil-vegetable or aqueous-vegetable agent, there are added in agitation natural may honey 6.0 g (6.0%) and formalin 0.6 g (0.6%); then the prepared agent is packed. The agent is applied externally, once or manifold on affected body part, or introduced internally.

EFFECT: invention allows ensuring higher clinical effectiveness with respect to inflammatory processes ensured by various actions of the components of the mixture.

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for prevention of inflammatory processes in animals. That is ensured by putting in a dark glass bottle at the relation g (wt %) of mixed dry powdered elecampane rhizomes and roots - 20.0 (5,9) plaster clover leaves, blossom, fruits, thin bodies - 14.5 (4.4), oak barks - 15.0 (4.4), touch-and-heal herb - 20.0 (5.9), calendula blossom basket - 20.0 (5,9), burnet bloodwort rhizomes and roots - 20.0 (5.9), lavender blossom clusters - 20.0 (5.9), peppermint leaves, bodies and blossom - 20.0 (5.9), costmary blossom baskets - 15.0 (4.4), common plantain leaves - 20.0 (5.9), horse gowan blossom - 20.0 (5.9), common licorice rhizomes, soboles - 20.0 (5.9), nosebleed herb - 20.0 (5.9), thyme herb - 20.0 (5.9), full-maturity hips - 20.0 (5.9), eucalyptus leaves - 20.0 (5.9), killwort leaves, bodies, blossom, fruits - 15.0 (4.4), and nonfrozen stoned sea-buckthorn fruits- 20.0 (5.9). Then agitated mixture is filled with 1500.0 g of corn or sunflower oils either plain or refined, or olive oil either plain or salad. The prepared mixture is kept at room temperature with constant mixing for 25-30 days with following separation of vegetable sediment and preparing of oil-vegetable agent. The prepared vegetable sediment is filled with 1500.0 g of 0.9% sterile solution of table salt at temperature no more than 50 C, and kept in agitation for 25-30 days to produce thereby an aqueous-vegetable agent. For each 100.0 g of prepared oil-vegetable or aqueous-vegetable agent, there are added in agitation natural may honey 6.0 g (6.0%) and formalin 0.6 g (0.6%); then the prepared agent is packed. The agent is applied externally, once or manifold on affected body part, or introduced internally.

EFFECT: invention allows ensuring higher clinical effectiveness with respect to inflammatory processes ensured by various actions of the components of the mixture.

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for prevention of inflammatory processes in animals. That is ensured by putting in a dark glass bottle at the relation g (wt %) of mixed dry powdered elecampane rhizomes and roots - 20.0 (5,9) plaster clover leaves, blossom, fruits, thin bodies - 14.5 (4.4), oak barks - 15.0 (4.4), touch-and-heal herb - 20.0 (5.9), calendula blossom basket - 20.0 (5,9), burnet bloodwort rhizomes and roots - 20.0 (5.9), lavender blossom clusters - 20.0 (5.9), peppermint leaves, bodies and blossom - 20.0 (5.9), costmary blossom baskets - 15.0 (4.4), common plantain leaves - 20.0 (5.9), horse gowan blossom - 20.0 (5.9), common licorice rhizomes, soboles - 20.0 (5.9), nosebleed herb - 20.0 (5.9), thyme herb - 20.0 (5.9), full-maturity hips - 20.0 (5.9), eucalyptus leaves - 20.0 (5.9), killwort leaves, bodies, blossom, fruits - 15.0 (4.4), and nonfrozen stoned sea-buckthorn fruits- 20.0 (5.9). Then agitated mixture is filled with 1500.0 g of corn or sunflower oils either plain or refined, or olive oil either plain or salad. The prepared mixture is kept at room temperature with constant mixing for 25-30 days with following separation of vegetable sediment and preparing of oil-vegetable agent. The prepared vegetable sediment is filled with 1500.0 g of 0.9% sterile solution of table salt at temperature no more than 50 C, and kept in agitation for 25-30 days to produce thereby an aqueous-vegetable agent. For each 100.0 g of prepared oil-vegetable or aqueous-vegetable agent, there are added in agitation natural may honey 6.0 g (6.0%) and formalin 0.6 g (0.6%); then the prepared agent is packed. The agent is applied externally, once or manifold on affected body part, or introduced internally.

EFFECT: invention allows ensuring higher clinical effectiveness with respect to inflammatory processes ensured by various actions of the components of the mixture.

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for prevention of inflammatory processes in animals. That is ensured by putting in a dark glass bottle at the relation g (wt %) of mixed dry powdered elecampane rhizomes and roots - 20.0 (5,9) plaster clover leaves, blossom, fruits, thin bodies - 14.5 (4.4), oak barks - 15.0 (4.4), touch-and-heal herb - 20.0 (5.9), calendula blossom basket - 20.0 (5,9), burnet bloodwort rhizomes and roots - 20.0 (5.9), lavender blossom clusters - 20.0 (5.9), peppermint leaves, bodies and blossom - 20.0 (5.9), costmary blossom baskets - 15.0 (4.4), common plantain leaves - 20.0 (5.9), horse gowan blossom - 20.0 (5.9), common licorice rhizomes, soboles - 20.0 (5.9), nosebleed herb - 20.0 (5.9), thyme herb - 20.0 (5.9), full-maturity hips - 20.0 (5.9), eucalyptus leaves - 20.0 (5.9), killwort leaves, bodies, blossom, fruits - 15.0 (4.4), and nonfrozen stoned sea-buckthorn fruits- 20.0 (5.9). Then agitated mixture is filled with 1500.0 g of corn or sunflower oils either plain or refined, or olive oil either plain or salad. The prepared mixture is kept at room temperature with constant mixing for 25-30 days with following separation of vegetable sediment and preparing of oil-vegetable agent. The prepared vegetable sediment is filled with 1500.0 g of 0.9% sterile solution of table salt at temperature no more than 50 C, and kept in agitation for 25-30 days to produce thereby an aqueous-vegetable agent. For each 100.0 g of prepared oil-vegetable or aqueous-vegetable agent, there are added in agitation natural may honey 6.0 g (6.0%) and formalin 0.6 g (0.6%); then the prepared agent is packed. The agent is applied externally, once or manifold on affected body part, or introduced internally.

EFFECT: invention allows ensuring higher clinical effectiveness with respect to inflammatory processes ensured by various actions of the components of the mixture.

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for prevention of inflammatory processes in animals. That is ensured by putting in a dark glass bottle at the relation g (wt %) of mixed dry powdered elecampane rhizomes and roots - 20.0 (5,9) plaster clover leaves, blossom, fruits, thin bodies - 14.5 (4.4), oak barks - 15.0 (4.4), touch-and-heal herb - 20.0 (5.9), calendula blossom basket - 20.0 (5,9), burnet bloodwort rhizomes and roots - 20.0 (5.9), lavender blossom clusters - 20.0 (5.9), peppermint leaves, bodies and blossom - 20.0 (5.9), costmary blossom baskets - 15.0 (4.4), common plantain leaves - 20.0 (5.9), horse gowan blossom - 20.0 (5.9), common licorice rhizomes, soboles - 20.0 (5.9), nosebleed herb - 20.0 (5.9), thyme herb - 20.0 (5.9), full-maturity hips - 20.0 (5.9), eucalyptus leaves - 20.0 (5.9), killwort leaves, bodies, blossom, fruits - 15.0 (4.4), and nonfrozen stoned sea-buckthorn fruits- 20.0 (5.9). Then agitated mixture is filled with 1500.0 g of corn or sunflower oils either plain or refined, or olive oil either plain or salad. The prepared mixture is kept at room temperature with constant mixing for 25-30 days with following separation of vegetable sediment and preparing of oil-vegetable agent. The prepared vegetable sediment is filled with 1500.0 g of 0.9% sterile solution of table salt at temperature no more than 50 C, and kept in agitation for 25-30 days to produce thereby an aqueous-vegetable agent. For each 100.0 g of prepared oil-vegetable or aqueous-vegetable agent, there are added in agitation natural may honey 6.0 g (6.0%) and formalin 0.6 g (0.6%); then the prepared agent is packed. The agent is applied externally, once or manifold on affected body part, or introduced internally.

EFFECT: invention allows ensuring higher clinical effectiveness with respect to inflammatory processes ensured by various actions of the components of the mixture.

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a dental care composition. The dental care composition for decreasing the degree of colour change in the dental care composition containing a humidifier, at least one abrasive compound, a vegetable extract containing one or more flavonoids, catechines, polyphenols and tannins; an antioxidant chosen from group of tin compounds, stannate compounds, ammonium sulphate, butylated hydroxytoluene and sodium metabisulphite and water in certain amount.

EFFECT: mentioned composition is effective in decreasing the degree of colour change in the dental care composition.

10 cl, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns a stable nonaqueous liquid composition for dental bleaching containing anhydrous peroxide compound dispersed in perorally acceptable mixture of anhydrous hydrophilic polymer and adhesion enhancing agent (adhesion enhancer). When applied locally on surface of teeth, said composition forms an adhesive (adherent) layer containing peroxide compound then released from said layer ensuring dental bleaching.

EFFECT: invention ensures a source of peroxide which is essentially decay-resistant in storage.

13 cl, 2 ex, 4 tbl

FIELD: articles for personal use.

SUBSTANCE: invention refers to the cosmetology and is the preliminary wiping agent to aid the anal region cleansing. The agent includes the base substrate and hydrophobic composition for adherence, and the composition against the adherence includes the softening agent, structurising agent, rheology modifier and compounds for the adherence. All the components of the composition are in certain mass ratios.

EFFECT: due to the reduction of the faecal material left in the anal refion after the defecation, this invention provides the improvement of the skin cleansing in the anal regions after the defecation.

5 cl

FIELD: articles for personal use.

SUBSTANCE: invention refers to the cosmetology and is the preliminary wiping agent to aid the anal region cleansing. The agent includes the base substrate and hydrophobic composition for adherence, and the composition against the adherence includes the softening agent, structurising agent, rheology modifier and compounds for the adherence. All the components of the composition are in certain mass ratios.

EFFECT: due to the reduction of the faecal material left in the anal refion after the defecation, this invention provides the improvement of the skin cleansing in the anal regions after the defecation.

5 cl

FIELD: medicine.

SUBSTANCE: invention concerns pharmacology and medicine. It involves water-salt extraction of Canadian goldenrod pollen pre-defatted by ethyl ester and dried. Extraction of fat-free and dried Canadian goldenrod pollen is carried out with Evans-Cook liquid during three days with daily agitation at temperature 15-26°C three times for 30-40 minutes every 1-1.5 hours. In intervals between agitations the material is kept at temperature 4-8°C. After extraction, supernatant fluid is poured out that is followed with centrifugation at 5000-6000 rpm within 30-40 minutes and filtration through a paper filter. Then sterilisation filtration, stabilisation of the mother liquor of allergen within 1-3 months and cultivation thereof after finished diagnostic allergen is made.

EFFECT: invention allows making a preparation not causing a sensitisation in animals in a diagnostic dose, possessing specific activity in reaction of indirect degranulation of rat's mast cells.

2 ex

Up!